MedTrace Logo

PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

NCT05685615 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-01-14

No results posted yet for this study

Summary

A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB

Conditions

  • Ventilator Associated Pneumonia

Interventions

DRUG

BV100 plus Polymyxin B

Rifabutin for Infusion plus Polymyxin B for Injection

DRUG

BAT

The best avaialble antibiotic therapy to treat CRAB

Sponsors & Collaborators

  • BioVersys AG

    lead INDUSTRY

Principal Investigators

  • Lisa Husband, MD · BioVersys SAS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-20
Primary Completion
2024-11-01
Completion
2024-12-11

Countries

  • Georgia
  • Greece
  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05685615 on ClinicalTrials.gov